Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Mots-C

Mitochondrial open reading frame of the 12S rRNA-c, MT-RNR1, Mitochondrial-derived peptide MOTS-c

Quick Stats
Studies 137
Trials 5
Score 2
2025 pubmed

MOTS-c as a Potential Diagnostic-prognostic Biomarker for Myocardial Infarction.

Cakmak. Abdulkadir A; Yazgan. Burak B

Key Findings

  • MOTS‑c levels were similar between myocardial infarction (MI) patients and controls overall.
  • Within the MI group, MOTS‑c levels changed over time (day 0, day 3, day 30).
  • Negative correlations were found: MOTS‑c vs. platelets at day 0 (r = -0.44) and MOTS‑c vs. troponin I at day 3 (r = -0.46).

Practical Outcomes

  • For biohackers, the main takeaway is that MOTS‑c is not yet a ready‑to‑use supplement or diagnostic tool for heart health. The peptide may become a future blood marker to gauge heart‑attack damage, but more research is needed before it can inform personal protocols or dosing strategies.

Summary

The study looked at a tiny mitochondrial peptide called MOTS‑c in heart‑attack patients. Overall levels of MOTS‑c weren’t different from healthy people, but the peptide changed over time after a heart attack and was linked to higher platelet counts and troponin I, two markers of heart damage. This hints that MOTS‑c might help doctors track heart‑attack severity, but it doesn’t tell us how to use it for self‑treatment.

Abstract

Myocardial infarction (MI) is a disease characterised by myocardial necrosis due to acute and prolonged ischaemic hypoxia in the coronary arteries. MOTS-c is a mitochondrial- derived peptide that has been reported to have protective effects on cardiac tissue. Although this peptide is thought to be decreased in various diseases and can serve as a potential biomarker, current studies remain limited. This study aimed to evaluate how the post-treatment process affects circulating MOTS- c peptide levels in myocardial infarction patients. For this purpose, patients without obstructive coronary lesions on angiography were included in the control group, while those with significant obstructive coronary lesions on angiography were included in the infarction group. Routine biochemistry tests were performed using an autoanalyzer. Besides, serum MOTS-c levels were measured using ELISA. Our findings showed CRP, ESR, and troponin I levels to be higher in the MI group compared to the control group. Also, there was no significant change in MOTS-c levels between the control and the MI group, while time-dependent changes (day 0, day 3, and day 30) occurred within the MI group. However, a negative correlation was found between MOTS-c and platelet levels in the MI group at day 0 (r: -0.4417, p =0.0450). Similarly, MOTS-c was found to be negatively correlated with troponin I in the MI group at day 3 (r: -0.4571, p =0.0372). The negative correlation of MOTS-c level with both platelet and troponin I has shown that this peptide may contribute to the diagnostic and therapeutic evaluation of the MI process along with other parameters.

Study Information

Provider

pubmed

Year

2025

Date

2025-05-09T00:00:00.000Z

DOI

10.2174/0118715257368076250324041741